mTOR and STAT3 Pathway Hyper-Activation is Associated with Elevated Interleukin-6 Levels in Patients with Shwachman-Diamond Syndrome: Further Evidence of Lymphoid Lineage Impairment
Open Access
- 4 March 2020
- Vol. 12 (3), 597
- https://doi.org/10.3390/cancers12030597
Abstract
Shwachman–Diamond syndrome (SDS) is a rare inherited bone marrow failure syndrome, resulting in neutropenia and a risk of myeloid neoplasia. A mutation in a ribosome maturation factor accounts for almost all of the cases. Lymphoid involvement in SDS has not been well characterized. We recently reported that lymphocyte subpopulations are reduced in SDS patients. We have also shown that the mTOR-STAT3 pathway is hyper-activated in SDS myeloid cell populations. Here we show that mTOR-STAT3 signaling is markedly upregulated in the lymphoid compartment of SDS patients. Furthermore, our data reveal elevated IL-6 levels in cellular supernatants obtained from lymphoblasts, bone marrow mononuclear and mesenchymal stromal cells, and plasma samples obtained from a cohort of 10 patients. Of note, everolimus-mediated inhibition of mTOR signaling is associated with basal state of phosphorylated STAT3. Finally, inhibition of mTOR-STAT3 pathway activation leads to normalization of IL-6 expression in SDS cells. Altogether, our data strengthen the hypothesis that SDS affects both lymphoid and myeloid blood compartment and suggest everolimus as a potential therapeutic agent to reduce excessive mTOR-STAT3 activation in SDS.Funding Information
- Ministero della Salute (GR-2016-02363570)
This publication has 52 references indexed in Scilit:
- Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying MechanismsClinical Cancer Research, 2017
- IL-6 biology: implications for clinical targeting in rheumatic diseaseNature Reviews Rheumatology, 2014
- JAKs and STATs in Immunity, Immunodeficiency, and CancerThe New England Journal of Medicine, 2013
- Targeting mTOR for the treatment of AML. New agents and new directionsOncotarget, 2011
- Uncoupling of GTP hydrolysis from eIF6 release on the ribosome causes Shwachman-Diamond syndromeGenes & Development, 2011
- Myelodysplastic syndromes: the complexity of stem-cell diseasesNature Reviews Cancer, 2007
- Interleukin-6 and its receptor: from bench to bedsideMedical Microbiology and Immunology, 2006
- CD3 bright lymphocyte population reveal γδ T cellsCytometry Part B: Clinical Cytometry, 2004
- gp130 Activation by Soluble Interleukin-6 Receptor/Interleukin-6 Enhances Osteoblastic Differentiation of Human Bone Marrow-Derived Mesenchymal Stem CellsExperimental Cell Research, 2002
- Immune function in patients with Shwachman–Diamond syndromeBritish Journal of Haematology, 2001